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Transient problems mainly occurred after high dose to the 
laryngeal and lower pharyngeal regions, combined with 
moderate dose to the upper pharyngeal region. The 
progressive pattern was mainly seen after moderate dose to 
the upper pharyngeal region. 
 
 
Conclusions: After definitive RT or CRT, five different 
patterns of swallowing dysfunction can be identified over 
time. This could reflect different underlying radiobiological 
mechanisms of radiation-induced damage and recovery. 
These results may improve identifying patients who are at 
the highest risk for developing severe persistent swallowing 
problems and who may benefit most from different 
preventive measures, such as swallowing sparing IMRT.  
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Purpose/Objective: Head and neck carcinoma of unknown 
primary (HNCUP) metastatic to cervical lymph nodes (LNs) 
constitutes about 2% of all head and neck carcinomas. There 
is no consensus on a standard radiotherapy clinical target 
volume (CTV) (ipsilateral neck only vs bilateral neck and 
mucosal tube) or dose to the CTV (50-70Gy). The aim of this 
combined analysis was to assess the safety and feasibility of 
total mucosal and bilateral neck intensity modulated 
radiotherapy (TM-IMRT). 
Materials and Methods: We performed a combined analysis 
of 2 single arm, phase 2 prospective trials (CCR2823 and 
CCR3301). All patients (pts) had PET-CT or CT staging, pan-
endoscopy and tonsillectomy or biopsy to exclude an occult 
primary. Patients with stage T0, N1-3, M0 (AJCC TNM 2002) 
disease were treated using a 5- to 7-field IMRT technique. 
CTV1 was the ipsilateral level 1b-5 and retropharyngeal (RP) 
LNs. CTV2 was the mucosa of nasopharynx, oropharynx, 
larynx, hypopharynx and contralateral cervical level 2 to 5 
and RP LNs. Prescribed doses to PTV1 and PTV2 in 30 
fractions were 60-65 Gy (depending on resection status R0 – 
60Gy, R1/R2 – 65 Gy) and 54 Gy, respectively. No 
prophylactic enteric feeding tubes were inserted. 
Results: Thirty-six pts (53% male) with HNCUP, median age of 
54.2 years (range 43-86.9 years), were treated between July 
2007 and December 2012. Histology was squamous cell 
carcinoma (SCC) in 35 pts or undifferentiated carcinoma 
nasopharyngeal type in 1 pt. Twenty-five (69%) pts were p16-
positive (surrogate for HPV) and 18 (50%) pts had a ≥10 pack 
year smoking history. Eighteen (50%) pts received 
chemoradiotherapy with concomitant platinum and 18 
(50%)pts radiotherapy (RT) alone. The median treatment time 
was 41 days (range 39-46 days). All pts received the 
prescribed dose with no clinically significant delays. The 2 
year locoregional control rate was 89.8% (95% CI, 78.4-100). 
The 2 year primary mucosal and local nodal control rates 
were 97.1% (95% CI, 91.4-100) and 89.8% (95% CI, 78.4-100) 
respectively. One mucosal primary (oropharynx) was 
detected 7.3 months (m) after RT and 2 patients died from 
recurrent metastatic SCC at 5.7m and 16.4m after RT. 
Twelve pts (33%) had acute (<3m after RT) grade 3 (LENT-
SOMA) dysphagia. The 1 year enteric tube feeding rate was 1 
of 36 (2.7%) pts. Rates of high grade, subjective xerostomia 
(LENT-SOMA, ≥grade 2) at 12m and 24m after RT were 17% 
and 15% respectively. 
Conclusions:At a median follow up of 33.5 months the use of 
TM-IMRT treating the total mucosal tube to an elective 
radiation dose of 54 Gy was associated with good local 
control rates. Toxicity is improved compared to previously 
reported TM-IMRT regimens encompassing similar mucosal 
volumes.  
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Purpose/Objective: Tumor hypoxia is a common feature of 
locally advanced head and neck cancer (HNSCC) that is 
associated with higher malignancy and increased 
radioresistance. The resolution of tumor hypoxia during 
fractionated radiation treatment is assumed to be pivotal for 
treatment success. 18F-fluoromisonidazole PET (F-MISO PET) 
allows noninvasive assessment of hypoxia during treatment. 
The purpose of the present study was to noninvasively assess 
the time course of tumor hypoxia and its correlation with 
additional imaging modalities and outcome. 
Materials and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
radiochemotherapy (RCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by Cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET scans and the coregistered F-MISO scans. At baseline MRI, 
FDG-PET and 1st F-MISO were acquired. Additional F-MISO 
scans were acquired in treatment weeks 2 and 5 (F-MISO2, 3). 
Endpoints were standardized uptake values (SUV) for PET 
scans, response on MRI scans (complete reponse (CR), partial 
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response (PR) or stable disease (SD)) and local tumor control. 
Indices of SUVmax in tumors/SUVmean in muscle were 
calculated for individual patients. Normalized SUV FDG 
(SUVmax tumor/SUV mean muscle) was plotted against 
normalized baseline SUV F-MISO1 (SUVmax tumor/SUV mean 
muscle) and the correlation was calculated. Follow-up 
included MRI every 3 months. 
Results: Patients undergoing definitive RCTx for SCCHN 
(n=16) were included. Tumor hypoxia was present in >90% of 
patients at baseline whereas at subsequent examinations 
hypoxia was sharply diminished in incidence (36% and 27%) 
and extent. On quantitative analysis the mean SUVmax 
indices decreased from 1.9 (week 0) to 1.6 (week 2) and 1.3 
(week 5). No correlation was found for normalized SUV FDG 
and the corresponding normalized baseline SUV F-MISO1 
(Pearson correlation coefficient 0.32). MRI scans obtained at 
treatment week 5 showed CR in 8 %, PR in 77 % and SD in 15 
% of patients. Kaplan-Meier analysis of local recurrence 
against time after treatment for a mean follow up of 39 
months showed significantly worse local tumor control for 
tumors hypoxic on F-MISO PET 1 and 2 (p<0.05) compared to 
non-hypoxic-tumors. 
Conclusions: Stable reduction of tumor hypoxia was found in 
the majority of patients. A significant correlation between 
tumor hypoxia obtained by F-MISO PET (F-MISO 1, 2) and local 
control was found.  
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Purpose/Objective: Radiotherapy (RT) for non-small cell lung 
cancer (NSCLC) may cause late toxicities, such as heart 
toxicity, changes in pulmonary function (PF) and lung 
fibrosis, but late toxicity data are scarce in the literature for 
this category of patients. The objective of this study was to 
analyze long term PF changes after definitive RT for patients 
with NSCLC. PF was measured by FEV1 and FVC as assessed by 
spirometry.  
Materials and Methods: This is a single institution study of 
patients receiving definitive RT for NSCLC between 1996 and 
2010. A total of 556 consecutive treated patients with 3063 
pairs of pulmonary function test (PFTs) were screened for 
eligibility for inclusion in the analysis of late changes in PF. 
To be eligible, patients had at least 3 PFTs after baseline. In 
this study, baseline was defined as 12 months after RT 
commencement to overcome a possible effect of tumor 
shrinkage and the acute side effect, radiation induced 
pneumonitis. PFT within 6 months prior to thoracic 
progression were excluded. The final study group comprised 
106 patients with 1286 pairs of PFTs. For each patient 
complete dosimetric data, including GTV, PTV, mean lung 
dose, Vx for total lung volume were available as well as 
patient specific pretreatment factors such as age, gender, 
smoking status, performance status, and pretreatment PF. 
Multivariable regression analyses were performed with 
patient, treatment, and dose-volume metrics as covariates to 
investigate their possible impact on long term PF. FEV1 and 
FVC were analyzed separately. 
Results: The long-term change in PF relative to the 1-year 
baseline was estimated by linear regression. Relative to the 
1-year-FEV1 most patients experienced a decrease in FEV1 
over time. The change in FEV1 per year, varied considerably 
among patients (Fig 1). Treatment year and V60 were the only 
covariates having a significant impact on FEV1 deterioration. 
Patients treated early in the period experienced a larger 
functional decline. Also for FVC a linear relationship with the 
follow-up time was found, again with large inter-patient 
variation. An unsuspected finding was that high V60 was 
associated with less decline in FVC, but FVC may be a less 
reliable parameter for pulmonary damage. 
 
Figure 1. Data on pulmonary function expressed in FEV1 from 
2 patients.The straight lines are the estimated loss, λ in the 
model. Zero denotes baseline, i.e. 12 months after start of 
radiotherapy. 
Conclusions: Patients experience a decline in FEV1 after the 
12-month value following definitive RT for NSCLC. In a 
multivariable analysis, deterioration of FEV1 was significantly 
associated with V60 of the lung (risk factor) and treatment 
year (risk factor). Early calendar year of treatment was 
associated with higher risk of deterioration. The yearly 
decline in FVC was less than in FEV1. A large V60 was, 
somewhat puzzling, associated with a lower FVC decline in a 
multivariable analysis. 
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Purpose/Objective: The state of oligometastases was divided 
into sync-oligometastases and oligo-recurrence, the 
